Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney

Europace

Volumn 10, Issue 10, 2008, Pages 1212-1217

  Bukowska, Alicja ^a   Lendeckel, Uwe ^a   Krohn, Alexander ^a   Keilhoff, Gerburg ^a   Have, Sara Ten ^a   Neumann, Klaus Hinrich ^a   Goette, Andreas ^a,b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Angiotensin; Arrhythmia; Fibrillation; Kidney; Oxidative stress; Pacing; Peptidase

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; COLLAGEN TYPE 1 ALPHA 3; IRBESARTAN; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; N(G),N(G) DIMETHYLARGININE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SWINE;

ANIMALS; ATRIAL FIBRILLATION; DOWN-REGULATION; FIBROSIS; KIDNEY; NEPRILYSIN; SIGNAL TRANSDUCTION; SWINE;

EID: 52949102124     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eun206     Document Type: Article

References (38)

1. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 1985;254:3449-53.
2. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-62.
3. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-26.
4. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 1996;94:2968-74.
5. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997;96:3157-63.
6. Pedersen OD, Sondergaard P, Nielsen T, Nielsen SJ, Nielsen ES, Falstie-Jensen N et al. Atrial fibrillation, ischaemic heart disease, and the risk of death in patients with heart failure. Eur Heart J 2006;27:2866-70.
7. Kober L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail 2006;8:591-8.
8. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997;29:709-15.
9. Kochiadakis GE, Skalidis EI, Kalebubas MD, Igoumenidis NE, Chrysostomakis SI, Kanoupakis EM et al. Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans. Eur Heart J 2002;23:734-41.
10. Range FT, Schafers M, Acil T, Schafers KP, Kies P, Paul M et al. Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. Eur Heart J 2007;28:2223-30.
11. Banerjee D, Ma JZ, Collins AJ, Herzog CA. Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2007;2:1186-90.
12. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, ADHERE Scientific Advisory Committee Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47:76-84.
13. Biber J, Stieger B, Stange G, Murer H. Isolation of renal proximal tubular brush-border membranes. Nat Protocols 2007;2:1356-9.
14. Venkatachalam MA, Jones DB, Rennke HG, Sandstrom D, Patel Y. Mechanism of proximal tubule brush border loss and regeneration following mild renal ischemia. Lab Invest 1981;45:355-65.
15. Rienstra M, Van Gelder IC, Van den Berg MP, Boomsama F, Van Veldhuisen DJ. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace 2006;8:482-7.
16. Wozakowska-Kaplon B, Opolski G, Janion M. Atrial natriuretic peptide before and after cardioversion of persistent atrial fibrillation. Kardiol Pol 2003;58:255-63.
17. Shelton RJ, Clark AL, Goode K, Rigby AS, Cleland JG. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. Eur Heart J 2006;27:2353-61.
18. Maric C, Zheng W, Walther T. Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase. Nephron Physiol 2006;103:149-56.
19. Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM et al. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int 2005;67:1723-30.
20. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007;8:970-82.
21. Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwohner M, Strugala D et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 2008;117:732-42.
22. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001;88:906-9.
23. Nattel S. Aldosterone antagonism and atrial fibrillation: time for clinical assessment? Eur Heart J 2005;26:2079-80.
24. Cengel A, Sahinarslan A, Biberoglu G, Hasanoglu A, Tavil Y, Tulmac M et al. Asymmetrical dimethylarginine level in atrial fibrillation. Acta Cardiol 2008;63:33-7.
25. Ngo DT, Heresztyn T, Mishra K, Marwick TH, Horowitz JD. Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA). Nitric Oxide 2007;16:197-201.
26. Bukowska A, Lendeckel U, Hirte D, Wolke C, Striggow F, Rohnert P et al. Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. Cell Mol Life Sci 2006;63:333-42.
27. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77.
28. Röcken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106:2091-7.
29. Seccia TM, Belloni AS, Guidolin D, Sticchi D, Nussdorfer GG, Pessina AC et al. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. J Hypertens 2006;24:1419-27.
30. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001;104:174-80.
31. Carnes CA, Chung MK, Nakayama T, Nakayama N, Baliga RS, Piao S et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001;89:e32-e38.
32. Dudley SC Jr, Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 2005;112:1266-73.
33. Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005;97:629-36.
34. Bukowska A, Schild L, Keilhoff G, Hirte D, Neumann M, Gardemann A et al. Mitochondrial dysfunction and redox signaling in atrial tachyaarhythmia. Exp Biol Med 2008;233:558-74.
35. Lentine KL, Schnitzler MA, Abbott KC, Li L, Xiao H, Burroughs TE et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol 2006;1:288-96.
36. Abbott KC, Reynolds JC, Taylor AJ, Agodoa LY. Hospitalized atrial fibrillation after renal transplantation in the United States. Am J Transplant 2003;3:471-6.
37. Bozbas H, Atar I, Yildirir A, Ozgul A, Uyar M, Ozdemir N et al. Prevalence and predictors of arrhythmia in end stage renal disease patients on hemodialysis. Ren Fail 2007;29:331-9.
38. Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008;51:255-62.